Nursing care
Amiodarone: what to check before you give it
Written and reviewed by Dana Whitfield, RN, MSN · 5 min read · Updated September 2026
Short answer
Amiodarone is a class III antiarrhythmic used for life-threatening ventricular arrhythmias and refractory atrial fibrillation, chosen when other agents fail or are contraindicated due to structural heart disease. Before it starts, get a baseline chest X-ray, TSH, and liver enzymes. Long-term use risks pulmonary fibrosis, thyroid dysfunction, corneal deposits, and a blue-grey skin discolouration.
Why this drug and not another
Amiodarone blocks potassium channels and prolongs the action potential and refractory period, but it also has sodium-channel, beta-blocking, and calcium-channel effects, making it the broadest-spectrum antiarrhythmic in routine use. That breadth is why it is reached for in ventricular fibrillation and pulseless ventricular tachycardia during resuscitation, and in atrial fibrillation when a patient has significant structural heart disease that rules out other agents.
It is chosen over narrower antiarrhythmics specifically because it carries a lower proarrhythmic risk in patients with reduced ejection fraction, where drugs like flecainide are contraindicated. The trade-off for that cardiac safety margin is the long list of extracardiac organs it affects, which is why it is generally reserved for arrhythmias that are refractory or life-threatening rather than used as first-line therapy.
Administration and timing
IV amiodarone for acute arrhythmias is given as a loading infusion followed by a maintenance infusion, and it must go through a central line when possible because peripheral administration risks phlebitis; if a peripheral line is unavoidable, use the largest vein available and monitor the site closely. It is compatible with normal saline or D5W and should be given with an in-line filter per institutional protocol.
Oral amiodarone has an unusually long half-life, measured in weeks, so a loading dose schedule is used to reach a therapeutic level faster, then tapered to a maintenance dose. Because of the long half-life, drug interactions and side effects can appear or persist long after a dose is missed or the drug is stopped, which is a detail that surprises patients used to short-acting medications.
Monitoring parameters
Baseline testing before the first dose includes a chest X-ray to catch pre-existing lung disease, thyroid function tests (TSH, and free T4 if TSH is abnormal), liver enzymes, and a baseline ECG for the QT interval and an ophthalmologic exam if therapy will be long-term. These baselines matter because amiodarone's toxicities develop insidiously and need a starting point for comparison.
Ongoing monitoring includes liver enzymes and thyroid function every 3 to 6 months, a chest X-ray or pulmonary function tests if respiratory symptoms develop, and periodic ECG for QT prolongation and bradycardia. During IV infusion, continuous cardiac monitoring and frequent blood pressure checks are needed, since hypotension and bradycardia are the acute risks.
Adverse effects to report
Pulmonary toxicity is the most serious long-term risk: new dyspnoea, dry cough, or fever should be reported and investigated promptly, since amiodarone-induced pulmonary fibrosis can progress and is sometimes irreversible if not caught early. Thyroid dysfunction can go either way, hypothyroidism or hyperthyroidism, because amiodarone is iodine-rich and affects thyroid hormone metabolism directly.
Corneal microdeposits are extremely common with long-term use and usually asymptomatic, occasionally causing visual halos, but they rarely require stopping the drug. A blue-grey discolouration of sun-exposed skin can develop after months to years of therapy and is a cosmetic effect that fades slowly after discontinuation. Liver enzyme elevation, peripheral neuropathy, and photosensitivity are also reportable findings, and any new visual disturbance or unexplained bruising warrants prompt evaluation.
Contraindications and cautions
Amiodarone is contraindicated in severe sinus node dysfunction or high-grade AV block without a functioning pacemaker, since it will worsen bradycardia and conduction delay. It is used cautiously in patients with pre-existing thyroid disease or significant lung disease, since it can exacerbate both.
It interacts significantly with warfarin, increasing INR and bleeding risk, so anticoagulant doses often need reduction after amiodarone is started. It also raises digoxin levels and interacts with other QT-prolonging drugs, statins metabolized through the same pathway, and grapefruit juice, which inhibits its metabolism and raises drug levels.
Teaching points the exam tests
Patients need to understand that amiodarone stays in the body for weeks after the last dose because of its long half-life, so side effects and interactions do not simply stop the day therapy ends. Sun protection is essential given both the photosensitivity risk and the skin discolouration risk; broad-spectrum sunscreen and protective clothing are standard advice.
Teach patients to report any new shortness of breath or persistent cough without delay, since early pulmonary toxicity caught on monitoring is far more manageable than fibrosis found late. Teach them to attend scheduled blood tests for thyroid and liver function even when feeling well, since these toxicities are often silent until advanced. Regular eye exams are advised for long-term users, and any new visual halos or blurred vision should be mentioned at the next visit rather than ignored.
The next step on this is the same as on everything else here: answer questions and read the rationales. Our cardiovascular practice questions are the closest set to what this page covers.
Common questions
Why does amiodarone need a baseline chest X-ray before starting?
Amiodarone can cause pulmonary fibrosis over months to years of use, and a baseline X-ray gives a starting point to judge whether new lung changes are drug-related later. Without it, early pulmonary toxicity is harder to distinguish from a pre-existing condition.
Can amiodarone be given through a peripheral IV?
It is preferably given through a central line because it is highly irritating to peripheral veins and can cause phlebitis, but a peripheral line can be used short-term in an emergency with the largest available vein and close site monitoring. It is switched to central access as soon as one can safely be placed.
Does amiodarone affect the thyroid permanently?
Not necessarily; amiodarone-induced hypothyroidism often resolves after the drug is stopped, while amiodarone-induced hyperthyroidism can be more persistent and sometimes needs separate treatment. Either way, thyroid function is checked periodically throughout therapy, not just at baseline.
Why does amiodarone interact so strongly with warfarin?
Amiodarone inhibits the liver enzymes that metabolize warfarin, which raises warfarin levels and INR even without a dose change. Warfarin doses are typically reduced when amiodarone is started, and INR is monitored more frequently during the transition.
More on cardiovascular
Guides on this